Europe Dry Eye Disease Market Forecast 2024-2032

The Europe dry eye disease market is projected to grow at a CAGR of 4.70% during the forecast period from 2024 to 2032. The market was valued at $1686.02 million in 2023, reaching a revenue of $2569.11 million by 2032.

MARKET INSIGHTS

The Europe dry eye disease market is set for consistent growth, driven by the aging population, increasing demand for dry eye disease treatment, and technological advancements in diagnostic and therapeutic products. Also, the region's dry eye disease market is characterized by the rising prevalence of dry eye disease across various age groups, influenced by lifestyle changes such as increased screen time and exposure to environmental pollutants.

REGIONAL ANALYSIS

The Europe dry eye disease market growth assessment comprises the analysis of the United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe. In the United Kingdom, increasing awareness of dry eye disease and growing government support are expected to drive market growth. The National Health Service (NHS) provides eye screening programs and helpline services for dry eye treatment. Additionally, ongoing research on dry eye disease in the UK further enhances growth prospects. In France, market expansion is driven by a growing number of treatment options and an increasing patient population.

Additionally, the growing geriatric population is a significant factor, as older individuals are more susceptible to conditions that impact tear production, leading to higher rates of dry eye disease. The rise in conditions like diabetes and autoimmune diseases, which are common dry eye disease causes, also contributes to the expanding patient base. Furthermore, heightened awareness about dry eye disease diagnosis and the availability of more advanced treatment options are pushing the demand for dry eye disease treatment products across the region.

Advancements in therapeutic and diagnostic products are enhancing the treatment of dry eye disease. The introduction of innovative dry eye disease treatment drugs and products, such as artificial tears, lubricants, and anti-inflammatory treatments, is improving patient outcomes. Moreover, the demand for dry eye disease treatment devices is rising as technological innovations in tear production and management devices continue to emerge.

SEGMENTATION ANALYSIS

The Europe dry eye disease market segmentation includes distribution channel, type, dosage, and product. The distribution channel segment is further divided into hospital pharmacies, online pharmacies/stores, and independent pharmacies and drugstores.

Retail pharmacies are independent establishments licensed to provide medications to the public. Over-the-counter (OTC) products form a key part of this distribution channel, making retail pharmacies a popular one-stop destination for these medications. The cost of OTC drugs at retail pharmacies is typically lower than those found in hospital pharmacies, providing an additional incentive for consumers to choose independent outlets.

Moreover, the retail pharmacy industry offers a seamless omnichannel experience, including home delivery services. There is also a growing trend towards in-home pharmacy services, as consumers prioritize convenience and explore digital-first pharmacy options, particularly in the wake of COVID-19. Many drugstores and small pharmacies are shifting from traditional models to technology-enabled ones, moving from in-person pickups to delivery services, which is expected to boost the growth of independent pharmacies.

Additionally, the increasing prevalence of dry eye disease is leading to more hospital visits, driving the demand for dry eye disease medications through hospital pharmacies. Pharmacists generally collaborate with other pharmacies to source supplies; however, in Eastern Europe, wholesalers are the main suppliers of pharmaceuticals. In contrast, in Western Europe, hospital pharmacists often procure supplies directly from manufacturers.

COMPETITIVE INSIGHTS

Some of the eminent market players in the Europe dry eye disease market are Santen Pharmaceutical Co Ltd, Novartis AG, Oasis Medical, etc.

Novartis AG is a Swiss-American multinational pharmaceutical company specializing in products for gene and cell therapies, as well as treatments for cancer, metabolic, and cardiovascular conditions. Its product portfolio includes biosimilars, generic medicines, vision care products, and ophthalmic pharmaceuticals.

The company has a global presence, operating in regions such as the Middle East & Africa, the Americas, Europe, and Asia-Pacific, with its headquarters located in Basel, Switzerland. One of its notable products, Xiidra(R) (lifitegrast ophthalmic solution) 5%, is the only prescription treatment approved to address the symptoms and signs of dry eye disease by inhibiting inflammation associated with the condition.

Product Code: 95051

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
- 2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
- 2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
- 2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
- 3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
- 3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
- 3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
- 3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
- 3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
- 4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
- 4.4.1. GROWTH PROSPECT MAPPING FOR EUROPE DRY EYE DISEASE MARKET
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
- 4.7.1. RESEARCH AND DEVELOPMENT
- 4.7.2. MANUFACTURING
- 4.7.3. DISTRIBUTORS
- 4.7.4. POST-SALES MONITORING

5. MARKET BY TYPE

5.1. OTC
5.2. PRESCRIPTION

6. MARKET BY PRODUCT

6.1. ANTI-INFLAMMATORY DRUGS
- 6.1.1. CYCLOSPORINE
- 6.1.2. CORTICOSTEROID
- 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS

7. MARKET BY DOSAGE

7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS

8. MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES

9. GEOGRAPHICAL ANALYSIS

9.1. EUROPE
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
- 9.1.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
- 9.1.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 9.1.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
- 9.1.6. COUNTRY ANALYSIS
  - 9.1.6.1.1. UNITED KINGDOM
  - 9.1.6.1.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.2. GERMANY
  - 9.1.6.2.1.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.3. FRANCE
  - 9.1.6.3.1.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.4. ITALY
  - 9.1.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.5. SPAIN
  - 9.1.6.5.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.6. BELGIUM
  - 9.1.6.6.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.7. POLAND
  - 9.1.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.8. REST OF EUROPE
  - 9.1.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES

10. COMPETITIVE LANDSCAPE

10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
- 10.2.1. ALCON
  - 10.2.1.1. COMPANY OVERVIEW
  - 10.2.1.2. PRODUCT LIST
  - 10.2.1.3. STRENGTHS & CHALLENGES
- 10.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
  - 10.2.2.1. COMPANY OVERVIEW
  - 10.2.2.2. PRODUCT LIST
  - 10.2.2.3. STRENGTHS & CHALLENGES
- 10.2.3. BAUSCH HEALTH COMPANIES INC
  - 10.2.3.1. COMPANY OVERVIEW
  - 10.2.3.2. PRODUCT LIST
  - 10.2.3.3. STRENGTHS & CHALLENGES
- 10.2.4. JOHNSON & JOHNSON
  - 10.2.4.1. COMPANY OVERVIEW
  - 10.2.4.2. PRODUCT LIST
  - 10.2.4.3. STRENGTHS & CHALLENGES
- 10.2.5. AFT PHARMACEUTICALS
  - 10.2.5.1. COMPANY OVERVIEW
  - 10.2.5.2. PRODUCT LIST
  - 10.2.5.3. STRENGTHS & CHALLENGES
- 10.2.6. LUMENIS
  - 10.2.6.1. COMPANY OVERVIEW
  - 10.2.6.2. PRODUCT LIST
  - 10.2.6.3. STRENGTHS & CHALLENGES
- 10.2.7. NOVALIQ GMBH
  - 10.2.7.1. COMPANY OVERVIEW
  - 10.2.7.2. PRODUCT LIST
  - 10.2.7.3. STRENGTHS & CHALLENGES
- 10.2.8. OASIS MEDICAL
  - 10.2.8.1. COMPANY OVERVIEW
  - 10.2.8.2. PRODUCTS LIST
  - 10.2.8.3. STRENGTHS & CHALLENGES
- 10.2.9. OTSUKA PHARMACEUTICAL CO LTD
  - 10.2.9.1. COMPANY OVERVIEW
  - 10.2.9.2. PRODUCT LIST
  - 10.2.9.3. STRENGTHS & CHALLENGES
- 10.2.10. SANTEN PHARMACEUTICAL CO LTD
  - 10.2.10.1. COMPANY OVERVIEW
  - 10.2.10.2. PRODUCTS LIST
  - 10.2.10.3. STRENGTHS & CHALLENGES
- 10.2.11. NOVARTIS AG
  - 10.2.11.1. COMPANY OVERVIEW
  - 10.2.11.2. PRODUCT LIST
  - 10.2.11.3. STRENGTHS & CHALLENGES
- 10.2.12. SENTISS PHARMA PRIVATE LIMITED
  - 10.2.12.1. COMPANY OVERVIEW
  - 10.2.12.2. PRODUCTS LIST
  - 10.2.12.3. STRENGTHS & CHALLENGES
- 10.2.13. TEVA PHARMACEUTICAL INDUSTRIES LTD
  - 10.2.13.1. COMPANY OVERVIEW
  - 10.2.13.2. PRODUCT LIST
  - 10.2.13.3. STRENGTHS & CHALLENGES
- 10.2.14. SUN PHARMACEUTICAL INDUSTRIES LTD
  - 10.2.14.1. COMPANY OVERVIEW
  - 10.2.14.2. PRODUCT LIST
  - 10.2.14.3. STRENGTHS & CHALLENGES
- 10.2.15. VISUFARMA
  - 10.2.15.1. COMPANY OVERVIEW
  - 10.2.15.2. PRODUCT LIST
  - 10.2.15.3. STRENGTHS & CHALLENGES

Product Code: 95051

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE MARKET
TABLE 2: EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 3: EUROPE DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: EUROPE DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: EUROPE DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: EUROPE DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 9: EUROPE DRY EYE DISEASE MARKET, BY DOSAGE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: EUROPE DRY EYE DISEASE MARKET, BY DOSAGE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 11: EUROPE DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: EUROPE DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 13: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 14: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 15: KEY PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET
TABLE 16: LIST OF MERGERS & ACQUISITIONS
TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 19: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR EUROPE DRY EYE DISEASE MARKET
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2023
FIGURE 8: EUROPE DRY EYE DISEASE MARKET, BY OTC, 2024-2032 (IN $ MILLION)
FIGURE 9: EUROPE DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2024-2032 (IN $ MILLION)
FIGURE 10: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2023
FIGURE 11: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 12: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2023
FIGURE 13: EUROPE DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2024-2032 (IN $ MILLION)
FIGURE 14: EUROPE DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2024-2032 (IN $ MILLION)
FIGURE 15: EUROPE DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 16: EUROPE DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2024-2032 (IN $ MILLION)
FIGURE 17: EUROPE DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2024-2032 (IN $ MILLION)
FIGURE 18: EUROPE DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2024-2032 (IN $ MILLION)
FIGURE 19: EUROPE DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 20: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DOSAGE, IN 2023
FIGURE 21: EUROPE DRY EYE DISEASE MARKET, BY EYE DROPS, 2024-2032 (IN $ MILLION)
FIGURE 22: EUROPE DRY EYE DISEASE MARKET, BY EYE SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 23: EUROPE DRY EYE DISEASE MARKET, BY OINTMENTS, 2024-2032 (IN $ MILLION)
FIGURE 24: EUROPE DRY EYE DISEASE MARKET, BY GELS, 2024-2032 (IN $ MILLION)
FIGURE 25: EUROPE DRY EYE DISEASE MARKET, BY CAPSULES & TABLETS, 2024-2032 (IN $ MILLION)
FIGURE 26: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2023
FIGURE 27: EUROPE DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2024-2032 (IN $ MILLION)
FIGURE 28: EUROPE DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUG STORES, 2024-2032 (IN $ MILLION)
FIGURE 29: EUROPE DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES/STORES, 2024-2032 (IN $ MILLION)
FIGURE 30: EUROPE DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 31: UNITED KINGDOM DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 32: GERMANY DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 33: FRANCE DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 34: ITALY DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 35: SPAIN DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 36: BELGIUM DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 37: POLAND DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 38: REST OF EUROPE DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)